Neurocrine signs $400M-plus deal with Idorsia for epilepsy drug

Swiss biotech Idorsia and Neurocrine Biosciences of the US have amended a deal signed last year to develop a new drug for childhood epilepsy, revealing it is worth more than $400 million.